MLI Certified Activities

Search
Generic filters
Credit Amount (at least)
Course Types
Learner Specialties
Therapeutics Areas
On the Cusp of a New Era in Treatment for Eosinophilic Esophagitits: Expert Insights on the Latest Advances in Targeted Therapy
In this activity, an expert in eosinophilic esophagitis discusses the latest research, data, and guidelines on novel and emerging targeted therapies.
Refractory Ascites and Esophageal Variceal Hemorrhage: Practical Guidance to Improve Patient Outcomes
In this activity, an expert on refractory ascites and esophageal variceal hemorrhage (EVH) discusses evidence-based strategies to improve patient outcomes.
Expanding the Benefits and Refining the Role of Immune Checkpoint Inhibitors in the Treatment of Recurrent and Advanced Endometrial Cancer
In this activity, an expert in oncology discusses the role of immune checkpoint inhibitors in the care of patients with recurrent and advanced endometrial cancer.
Interprofessional Perspectives on Safety Management With Targeted Therapy for B-cell Malignancies
In this activity, a hematologist-oncologist, cardiologist, oncology nurse, and pharmacist team up to discuss targeted agents (including BTK and BCL-2 inhibitors) in B-cell malignancies and how the team works closely together to manage toxicity and safety concerns associated with targeted therapies. Case scenarios are presented to illustrate how a collaborative approach is not only necessary for managing patients with B-cell cancers, such as CLL and MCL, but can also improve patient outcomes through monitoring and managing adverse events.
Episode 1 of 4 of the series on: The Evolving Role of CAR T-cell Therapy for R/R B-cell Lymphomas: Improving Access and Outcomes
It’s Time to Understand CAR-T Therapy for B-cell Lymphoma: Earlier Indications Coming to a Community Near You, episode 1 of the 4-part educational initiative, The Evolving Role of CAR T-cell Therapy for R/R B-cell Lymphomas: Improving Access and Outcomes, is designed for community-based oncology clinicians. This CE activity includes conversations among CAR-T experts and a community clinician; it includes animations, patient video clips, and numerous downloadable resources including a directory of CAR-T treatment centers organized by state. This activity explains what CAR-T therapy is and how it works; a special guest highlights key data from completed and ongoing trials of CAR-T therapies that were presented during the recent hematology conference.
Visualizing Progress for TP53 Mutant AML: A Pathology-Guided Journey through Diagnostic Principles and Modern Treatment
In this activity, an expert pathologist discusses the prognostic relevance of TP53 mutations, current diagnostic tools and principles for capturing TP53-mutated acute myeloid leukemia (AML), and new developments with innovative therapy for TP53-mutated AML.
New Insights How Does Real-World Evidence Influence VTE Management? A Visual Exploration of Real-World Studies of DOACs
In this activity, a vascular medicine expert discusses real-world evidence (RWE) for treating patients with or at risk for venous thromboembolism (VTE) with direct oral anticoagulants (DOACs).
Acute Hepatic Porphyria: Disease Diagnosis and Revelations Regarding the Role of siRNA Therapy
In this activity, a leading expert in the management of acute hepatic porphyria (AHP) discusses recent evidence and recommendations for treating AHP and highlights the rationale and role of a new siRNA-based therapeutic option.
Selective Inhibition of Oncogenic Transcription and Other Novel Approaches in the Treatment of Small Cell Lung Cancer: An Illustrative Guide to Navigating the Evolving Treatment Landscape and Integrating Latest Treatment Modalities Into Clinical Care
In this activity, an expert in small cell lung cancer provides an overview of the features and challenges associated with the condition, as well as the current treatment landscape.
New and Emerging Therapeutic Strategies in Bladder Cancer: Updates in Early-Stage Disease and Beyond
In this activity, an expert in genitourinary oncology discusses new and emerging strategies for the management of patients with bladder cancer.
Conversations on the New Wave of Innovative Therapy in Follicular Lymphoma: Implications for Personalized Medicine
In this activity, two lymphoma experts discuss the newest treatment options for follicular lymphoma (FL). Hear what Drs. John Pagel and Ian Flinn have to say about recent evidence supporting a personalized approach to treating patients with relapsed FL, including the integration and use of novel targeted options, such as PI3K and EZH2 inhibitors. The experts also provide their insights on baseline factors that can help identify patients who may benefit from the use of such innovative agents, as well as safety management.
Beyond TNF Inhibitors: Latest and Emerging Evidence on Novel Cytokine-Modulating Strategies in the Treatment of Moderate to Severe Psoriasis
In this activity, an expert in dermatology discusses the latest evidence on novel cytokine-modulating strategies in the treatment of moderate to severe psoriasis.
Examining Novel Approaches to Improve the Management of Influenza: An Animated Exploration
In this activity, an influenza expert discusses the latest clinical evidence and current guideline recommendations on the use of antiviral therapy in the treatment of influenza.
Episode 4 of 4 of the series on: The Evolving Role of CAR T-cell Therapy for R/R B-cell Lymphomas: Improving Access and Outcomes
Opening the CAR(T) Door to Get Patient to Therapy, episode 4 of the 4-part educational initiative The Evolving Role of CAR T-cell Therapy for R/R B-cell Lymphomas: Improving Access and Outcomes, is designed for community-based oncology clinicians. This CE activity includes conversations among CAR-T experts and a community clinician; it includes patient video clips and numerous downloadable resources including a directory of CAR-T treatment centers organized by state. This activity focuses on managing logistics associated with CAR-T therapy, including common misperceptions, the numerous services offered by treating centers, and how to overcome roadblocks for your patients.
Episode 2 of 3: Overcoming Barriers to Prescribing: A Med Table Talk™: Targeted Therapy in Atopic Dermatitis Series
In episode 2 of the 3-part educational initiative TRANSFORMING TARGETED THERAPY IN ATOPIC DERMATITIS: APPLYING EMERGING DATA AND EVOLVING BEST PRACTICES TO IMPROVE OUTCOMES, dermatologists and allergists discuss overcoming barriers to the use of oral JAK inhibitors. This activity focuses on the mechanistic rationale for the benefit and risk profiles of oral JAK inhibitors, how to address the black box warnings, and making treatment decisions based on patients’ values and goals.
Taking it From the Top: Targeting a New Approach to Control Severe Asthma
In this activity, experts in asthma detail the pathophysiology of severe asthma, with a discussion of the underlying mechanisms behind both type 2 and non–type 2 asthma, and novel and emerging therapies for its treatment.
The Rising Tide of Novel BTK Inhibitors: Case-Based Guidance on Overcoming Intolerance, Resistance, and Other Clinical Challenges in B-Cell Cancers
The Rising Tide of Novel BTK Inhibitors: Case-Based Guidance on Overcoming Intolerance, Resistance, and Other Clinical Challenges in B-Cell Cancers
Solving the Challenge of Tumor Lysis Syndrome: Expert Insight and Guidance on a Challenging Oncologic Emergency
Tumor lysis syndrome (TLS) is a serious and potentially fatal oncologic emergency that, paradoxically, is partially linked to the use of highly effective anticancer treatment. How can the management team rise to the challenge of TLS? In this activity, Anthony R. Mato, MD, MSCE, and Kristen Battiato, MSN, RN, AGNP-C, will provide an answer. Join them as they explore team-based management of TLS and provide guidance on developing TLS management plans. Throughout this program, the experts will use real-world case scenarios to demonstrate how professionals can work together to identify risk factors for TLS, recognize its laboratory and clinical symptoms, and prevent its occurrence.
Strategies To Improve Glucose Control with Mealtime Insulin
This CME/NCPD/CPE activity includes five individual interactive, microlearning modules addressing care and outcomes for individuals with diabetes treated with mealtime insulin (MTI).  The modules incorporate case studies with embedded questions for an active learning experience. Learners can choose to participate in one or more of the modules to address their educational interests and needs based on their scope of practice and patient population.
Strategies for Controlling Glucose with MTI
This CME/NCPD/CPE activity includes five individual interactive, microlearning modules addressing care and outcomes for individuals with diabetes treated with mealtime insulin (MTI). The modules incorporate case studies with embedded questions for an active learning experience. Learners can choose to participate in one or more of the modules to address their educational interests and needs based on their scope of practice and patient population.
Overcoming Challenges in the Recognition and Management of Adult ADHD in Primary Care: Optimizing Outcomes to Reduce Disease Burden and Improve Quality of Life
In this activity, experts in attention-deficit/hyperactivity disorder (ADHD) discuss overcoming challenges in the recognition and management of adult ADHD in primary care.
Leading the Way to Optimal Care in Multiple Myeloma: Nurse Perspectives on the Practicalities and Potential of Novel Therapeutics
In this activity, a nurse expert discusses novel therapeutics in multiple myeloma and the important role nurses play in the treatment of this disease.
Inflammatory Bowel Disease Management Through Tele-Health: Navigating the New Normal
During the COVID-19 pandemic clinicians are quickly having to change their patient management strategies to help control conditions during an unparalleled time with a stressed healthcare system, social –distancing, and fear of infection for vulnerable populations. By learning how to use telemedicine correctly clinicians can help to keep their patients with inflammatory bowel disease (IBD) properly managed and safe from COVID-19 infection through virtual interventions.
A Personalized Approach to Guide Risk-Adapted Treatment Decisions in Myelofibrosis: Applying the Latest Clinical Evidence on JAK Inhibitors and Novel Combination Therapies to Improve Patient Outcomes
In this activity, hematology-oncology experts discuss the current and emerging therapeutic options for the management of patients with myelofibrosis.
Scroll to Top